pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK
Regeneron UK Limited
NovaPharmaNews editorial coverage mentioning Regeneron UK — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Tarrytown, USA
- Employees
- 16,715
- Programs
- 493
- Drugs
- 98
- Patents
- 837
News & analysis
NovaPharmaNews articles mentioning Regeneron UK — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Regeneron UK — regulatory, clinical, and market analysis.
FDA approves Dupixent for COPD with eosinophilic phenotype
The FDA has approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. The decision gives Regeneron and Sanofi a new regulatory catalyst to track for commercial and investor implications.
Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment
Regeneron Pharmaceuticals' stock shows resilience despite a recent analyst price target reduction and ongoing European Medicines Agency (EMA) review of an eye drug. The market appears to be absorbing these developments without significant share price volatility.
Parabilis IPO Plans Following Regeneron Deal: What You Need to Know
Parabilis has announced its IPO plans just a day after the Regeneron deal, signaling a surge in listings. This article explores the implications for the pharmaceutical landscape.
Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights
Regeneron Pharma stock is in the spotlight following significant institutional buying. This article explores the implications for investors and pharma teams.
Regeneron's Phase 3 Skin Cancer Trial Failure: Implications for LAG-3
Regeneron's recent Phase 3 trial failure for skin cancer highlights significant challenges in LAG-3 research. This article explores the implications for the pharmaceutical landscape.
Regeneron Secures $125M Parabilis Deal for Drug Targets
Regeneron has entered a significant $125M deal with Parabilis to target elusive drug targets. This partnership could reshape competitive dynamics in the pharmaceutical industry.
Regeneron's Phase 3 Skin Cancer Miss: Implications for LAG-3 Development
Regeneron's recent Phase 3 trial failure in skin cancer highlights ongoing challenges in LAG-3 research. This article examines the implications for the pharmaceutical industry.
Regeneron Immunotherapy Combo Fails in Melanoma Trial
Regeneron's recent melanoma trial results raise questions about the future of its immunotherapy combo. Analysts must assess the competitive landscape and investment implications.